ftc
parbradyphoto / iStockphoto.com
18 September 2017Americas

FTC secures partial win against AbbVie

The Federal Trade Commission (FTC) has secured a partial victory in its competition case against life sciences company AbbVie.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
24 February 2017   The Federal Trade Commission has found after a public comment period that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would probably be anti-competitive.
Americas
2 July 2018   Pharmaceutical companies AbbVie and Besins Healthcare have been ordered to pay the US Federal Trade Commission $448 million for using “sham litigation” to block access to generic versions of a testosterone drug.
Americas
2 October 2020   A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.

More on this story

Americas
24 February 2017   The Federal Trade Commission has found after a public comment period that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would probably be anti-competitive.
Americas
2 July 2018   Pharmaceutical companies AbbVie and Besins Healthcare have been ordered to pay the US Federal Trade Commission $448 million for using “sham litigation” to block access to generic versions of a testosterone drug.
Americas
2 October 2020   A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.

More on this story

Americas
24 February 2017   The Federal Trade Commission has found after a public comment period that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would probably be anti-competitive.
Americas
2 July 2018   Pharmaceutical companies AbbVie and Besins Healthcare have been ordered to pay the US Federal Trade Commission $448 million for using “sham litigation” to block access to generic versions of a testosterone drug.
Americas
2 October 2020   A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.